Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 20,000 shares at $38.32 ($766K) on 2025-12-16, disclosed to the SEC on 2025-12-17.
Scheduled sale ($766k) by EVP, Research & Investments under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |